Valeant further slashed its guidance for 2016 as the Canadian drugmaker pushes to dig out of what it called months of ‘significant disruption’ to its business as CEO Joseph Papa seeks to rebuild investor confidence.
from WSJ.com: US Business http://ift.tt/1ZukTAv
via IFTTT
No comments:
Post a Comment